The mortality rate for cervix uteri malignant neoplasms in Canada from 2024 to 2028 shows a slight decline from 2.2 to 2.1 deaths per hundred thousand women. In 2023, this rate was consistent with 2024 at 2.2. There is no significant year-on-year variation observed, indicating stable mortality rates with approximately 0% change annually. Over a five-year period, the CAGR reflects a minimal decrease, indicating steady mortality rates with minor improvements.
Future trends to watch for include advancements in early detection and screening technologies, which may further reduce mortality rates. Additionally, increased awareness and vaccination efforts against HPV could have a long-term positive impact on these figures.
